No Data
No Data
Express News | Zyversa Therapeutics Inc Files for Mixed Shelf Offering of up to $100 Mln - SEC Filing
Express News | Zyversa Therapeutics Inc: Glp Toxicology Studies Scheduled to Begin H2-2024
ZyVersa Therapeutics 2Q Loss/Shr $3.31 >ZVSA
Express News | Zyversa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
10-Q: Q2 2024 Earnings Report
Express News | ZyVersa Therapeutics Announces Data Published In The Peer-reviewed Journal Demonstrating That Extracellular ASC Has A Crucial Role In Aggregation And Deposition Of Amyloid A Fibrils Leading To Associated Chronic Inflammatory Conditions
No Data
No Data